Morning Overview on MSN
A single-shot gene-silencing therapy just cut dangerous cholesterol in half for a full year — built to replace the daily statins millions of adults already take
About half of all adults prescribed a statin stop taking it within a year. They forget, they dislike the side effects, or ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PARIS — Inclisiran, an investigational ...
Morning Overview on MSN
A single shot just slashed dangerous cholesterol levels for a full year in a late-stage trial — a gene-silencing therapy built to replace the daily statins millions take
For the roughly 200 million people worldwide who take a statin every day, the routine is deceptively simple: swallow a pill, ...
ATLANTA, GA—Using inclisiran (Leqvio; Novartis) as soon as possible in the care of patients with atherosclerotic cardiovascular disease (ASCVD) is associated with sustained lowering of LDL cholesterol ...
Instead of popping a pill every day, people might soon control “bad” LDL cholesterol by getting an injection at their doctor’s office two or three times a year. Researchers testing a new injectable ...
Inclisiran, an investigational small interfering RNA (siRNA) that inhibits production of the PCSK9 protein in the liver, significantly lowers LDL-cholesterol levels across a range of different ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. NEW ORLEANS — Inhibition of PCSK9 synthesis via RNA ...
The phase 3 ORION-11 study of inclisiran sodium met all primary and secondary end points, with efficacy consistent with findings from phase 1 and 2 studies, The Medicines Company announced today ORION ...
Three phase 3 trials of the novel small-interfering RNA (siRNA) agent inclisiran (The Medicines Company) have been published, all showing an approximate halving of LDL cholesterol levels with the drug ...
More patients with hypercholesterolemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran compared with placebo, when ...
Inclisiran lowers low-density lipoprotein (LDL; 'bad') cholesterol for up to one year in patients with high cardiovascular risk and elevated LDL cholesterol. Inclisiran lowers low-density lipoprotein ...
A new anti-cholesterol jab could save 30,000 lives within a decade when it is made available on the NHS in England and Wales. Inclisiran, which is set to be offered to hundreds of thousands of people, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results